Clinical Trial Update: A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy [Phase 2]

View source ↗

Summary

Phase II double-blind trial evaluating recombinant human nerve growth factor for HIV-associated sensory neuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Peripheral Nervous System Disease

Drugs mentioned

• Recombinant human nerve growth factor (Nerve Growth Factor)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections, Peripheral Nervous System Disease | Phase 2 | Status: COMPLETED